Lovastatin and extended-release niacin combination product: The first drug combination for the management of hyperlipidemia

Heart Disease

Volumn 4, Issue 2, 2002, Pages 124-137

  Gupta, Eric K ^a   Ito, Matthew K ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN A; ASCORBIC ACID; BETA CAROTENE; COLESTIPOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; SELENIUM; SIMVASTATIN;

BIOEQUIVALENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; LIVER TOXICITY; METABOLIC DISORDER; MYOPATHY; PRESCRIPTION; REVIEW; SUSTAINED RELEASE PREPARATION;

EID: 0036124116     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200203000-00010     Document Type: Review

References (55)

1. Rationale and design of the cardiac hospitalization atherosclerosis management program at the University of California Los Angeles
2. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Heart protection study
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
7. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
9. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
10. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
11. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
12. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
13. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
14. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study
15. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
16. Atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease risk
17. Drug therapy for hypercholesterolemia and dyslipidemia
18. Expanded clinical evaluation of lovastatin (EXCEL) study results
19. Management of primary mixed hyperlipidemia with lovastatin
20. Differential effects of nicotinic acid in subjects with different LDL subclass patterns
21. Mechanistic studies of high-density lipoproteins
22. Treatment effect of extended-release niacin, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial
23. A new extended-release niacin (extended-release niacin): Efficacy, tolerability, and safety in hypercholesterolemic patients
24. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
25. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia
26. Safety and effectiveness of extended-release niacin when added sequentially to a statin for treatment of dyslipidemia
27. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia
28. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/dl in patients with hyperlipidemia and coronary artery disease
29. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated
30. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotcin cholesterol
31. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
32. Differences in metabolism of time-release and unmodified nicotinic acid: Explanation of the differences in hypolipidemic action?
33. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
34. Coronary angiographic changes with lovastatin therapy: The Monitored atherosclerosis regression study (MARS)
35. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized, controlled clinical trial
36. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian coronary atherosclerosis intervention trial
37. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
38. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
39. Equivalent efficacy of time-release form of niacin (extended-release niacin) given once-a-night versus plain niacin in the management of hyperlipidemia
40. Clofibrare and niacin in coronary heart disease
41. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
42. Beneficial effects or combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
43. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
44. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B
45. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
46. Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
47. Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin
48. Effect of niacin on atherosclerotic cardiovascular disease
49. Tolerance to nicotinic acid flushing
50. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: A randomized trial
51. Effects of extended-release niacin on lipoproteins and glycemic control in patients with type 2 diabetes mellitus: Results of a randomized, double-blind, placebo-controlled trial